Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic : Results from the EPICOVIDEHA registry
© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd..
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109 /L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Hematological oncology - 42(2024), 1 vom: 10. Jan., Seite e3240 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 31.01.2024 Date Revised 31.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hon.3240 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365413593 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365413593 | ||
| 003 | DE-627 | ||
| 005 | 20240131231955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hon.3240 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM365413593 | ||
| 035 | |a (NLM)38050405 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Musto, Pellegrino |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic |b Results from the EPICOVIDEHA registry |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2024 | ||
| 500 | |a Date Revised 31.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd. | ||
| 520 | |a Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 109 /L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a hematological malignancy | |
| 650 | 4 | |a multiple myeloma | |
| 700 | 1 | |a Salmanton-García, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Sgherza, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Bergantim, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Farina, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Glenthøj, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Cengiz Seval, Guldane |e verfasserin |4 aut | |
| 700 | 1 | |a Weinbergerová, Barbora |e verfasserin |4 aut | |
| 700 | 1 | |a Bonuomo, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Bilgin, Yavuz M |e verfasserin |4 aut | |
| 700 | 1 | |a van Doesum, Jaap |e verfasserin |4 aut | |
| 700 | 1 | |a Jaksic, Ozren |e verfasserin |4 aut | |
| 700 | 1 | |a Víšek, Benjamín |e verfasserin |4 aut | |
| 700 | 1 | |a Falces-Romero, Iker |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetti, Monia |e verfasserin |4 aut | |
| 700 | 1 | |a Dávila-Valls, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Pérez, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Nucci, Marcio |e verfasserin |4 aut | |
| 700 | 1 | |a López-García, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Itri, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Buquicchio, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Verga, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Piukovics, Klára |e verfasserin |4 aut | |
| 700 | 1 | |a Navrátil, Milan |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Graham P |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez, Moraima |e verfasserin |4 aut | |
| 700 | 1 | |a Fracchiolla, Nicola S |e verfasserin |4 aut | |
| 700 | 1 | |a Labrador, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Prezioso, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Čolović, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Meers, Stef |e verfasserin |4 aut | |
| 700 | 1 | |a Kulasekararaj, Austin |e verfasserin |4 aut | |
| 700 | 1 | |a Cuccaro, Annarosa |e verfasserin |4 aut | |
| 700 | 1 | |a Blennow, Ola |e verfasserin |4 aut | |
| 700 | 1 | |a Valković, Toni |e verfasserin |4 aut | |
| 700 | 1 | |a Sili, Uluhan |e verfasserin |4 aut | |
| 700 | 1 | |a Ledoux, Marie-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Batinić, Josip |e verfasserin |4 aut | |
| 700 | 1 | |a Passamonti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte, Rafael F |e verfasserin |4 aut | |
| 700 | 1 | |a Poulsen, Christian Bjørn |e verfasserin |4 aut | |
| 700 | 1 | |a Méndez, Gustavo-Adolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Espigado, Ildefonso |e verfasserin |4 aut | |
| 700 | 1 | |a Demirkan, Fatih |e verfasserin |4 aut | |
| 700 | 1 | |a Čerňan, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Cattaneo, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Petzer, Verena |e verfasserin |4 aut | |
| 700 | 1 | |a Magliano, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Vidal, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a El-Ashwah, Shaimaa |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes-Da-Silva, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Vena, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Ormazabal-Vélez, Irati |e verfasserin |4 aut | |
| 700 | 1 | |a van Praet, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Dargenio, Michelina |e verfasserin |4 aut | |
| 700 | 1 | |a De-Ramón, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Del Principe, Maria Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Marques-De-Almeida, Joyce |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Dominik |e verfasserin |4 aut | |
| 700 | 1 | |a Szotkowski, Tomáš |e verfasserin |4 aut | |
| 700 | 1 | |a Obr, Aleš |e verfasserin |4 aut | |
| 700 | 1 | |a Çolak, Gökçe Melis |e verfasserin |4 aut | |
| 700 | 1 | |a Nordlander, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Izuzquiza, Macarena |e verfasserin |4 aut | |
| 700 | 1 | |a Cabirta, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Zambrotta, Giovanni Paolo Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Cordoba, Raul |e verfasserin |4 aut | |
| 700 | 1 | |a Žák, Pavel |e verfasserin |4 aut | |
| 700 | 1 | |a Ammatuna, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Jiří |e verfasserin |4 aut | |
| 700 | 1 | |a Ilhan, Osman |e verfasserin |4 aut | |
| 700 | 1 | |a García-Sanz, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Quattrone, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Arellano, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes-Rodrigues, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Emarah, Ziad |e verfasserin |4 aut | |
| 700 | 1 | |a Aiello, Tommaso Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Hanakova, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Ráčil, Zdeněk |e verfasserin |4 aut | |
| 700 | 1 | |a Bavastro, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Limongelli, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Rahimli, Laman |e verfasserin |4 aut | |
| 700 | 1 | |a Marchesi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Cornely, Oliver A |e verfasserin |4 aut | |
| 700 | 1 | |a Pagano, Livio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematological oncology |d 1993 |g 42(2024), 1 vom: 10. Jan., Seite e3240 |w (DE-627)NLM012648280 |x 1099-1069 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:1 |g day:10 |g month:01 |g pages:e3240 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hon.3240 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 1 |b 10 |c 01 |h e3240 | ||